Crystalys Therapeutics
Crystalys Therapeutics develops dotinurad, an oral URAT1 inhibitor for treating gout
$130MSeries B
Role not disclosedSO
SR One
Activity from announced rounds
Activity in this selectionOct 25, 2026 · Biotech · Jan 1, 2026
- Rounds participated in
- 6
- Confirmed lead rounds
- 0 5 roles undisclosed
- New companies
- 5 First participation on record · 1 follow-on
- Funding in participating rounds
- $490M 5 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
6 in this selectionDraig Therapeutics
Draig Therapeutics develops neuropsychiatric medicines.
$65MSeries B
Role not disclosedPoplar Therapeutics
Developing a new class of anti-IgE therapy to treat food allergy and other atopic conditions
$45MSeries A+
Role not disclosedCorxel Pharmaceuticals
Corxel Pharmaceuticals develops clinical-stage medicines for cardiometabolic diseases, including obesity, diabetes, stroke and hypertension.
≤$287MSeries D1
ParticipantAirNexis Therapeutics
AirNexis Therapeutics develops medicines for pulmonary diseases, led by the investigational COPD candidate AN01.
$200MSeries A
Role not disclosedPoplar Therapeutics
Developing a new class of anti-IgE therapy to treat food allergy and other atopic conditions
$50MSeries A
Role not disclosed